CSL gets top-line boost thanks to a post-pandemic boom in plasma collections

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 billion acquisition of Swiss blood specialist Vifor—has rekindled the growth of Australia’s largest biotech.